Provided by Tiger Trade Technology Pte. Ltd.

Keros Therapeutics, Inc.

11.23
+0.16001.45%
Post-market: 11.230.00000.00%16:20 EDT
Volume:97.97K
Turnover:1.10M
Market Cap:222.66M
PE:-3.62
High:11.49
Open:11.07
Low:10.97
Close:11.07
52wk High:22.55
52wk Low:9.69
Shares:19.83M
Float Shares:18.25M
Volume Ratio:0.58
T/O Rate:0.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1046
EPS(LYR):2.30
ROE:-17.16%
ROA:-11.78%
PB:0.85
PE(LYR):4.88

Loading ...

Keros Therapeutics - Received $200 Mln Upfront from Takeda, Eligible for over $1.10 Bln in Milestones

THOMSON REUTERS
·
Jul 31

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

THOMSON REUTERS
·
Jul 31

Keros Therapeutics - Appoints Annita Tanini Interim Principal Financial Officer Effective August 4, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 23

Keros Therapeutics Names Annita Tanini Interim CFO as Keith Regnante Resigns

Reuters
·
Jul 23

Keros Therapeutics Director Jean Jacques Bienaime Buys USD 10,610 in Common Shares

Reuters
·
Jul 18

Keros Therapeutics Director Anne Prener Files Initial Beneficial Ownership Statement

Reuters
·
Jul 07

Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors

TIPRANKS
·
Jul 03

Keros Therapeutics Appoints Anne Prener to Its Board of Directors

THOMSON REUTERS
·
Jun 26

Keros Therapeutics director Jean Jacques Bienaime buys $10,190 of common shares

Reuters
·
Jun 18

Keros director Charles W. Newton sells 550 shares for $5,522

Reuters
·
Jun 16

Keros Therapeutics director Nima Farzan sells 2,625 shares for $28,163.25

Reuters
·
Jun 09

Keros Therapeutics director Julius Knowles sells 2,625 shares for $28,163.25

Reuters
·
Jun 09

Keros Therapeutics director Seth Alpna disposes of 2,625 shares worth $28,140.00

Reuters
·
Jun 06

Keros Therapeutics holds annual shareholder meeting

Reuters
·
Jun 04

Keros Therapeutics CEO to join Goldman Sachs Global Healthcare Conference fireside chat

Reuters
·
Jun 02

Keros director Jean Jacques Bienaime acquires $10,580 common shares

Reuters
·
May 20

Analysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (RGNX), Align Tech (ALGN) and Keros Therapeutics (KROS)

TIPRANKS
·
May 15

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS) and Pelthos Therapeutics (PTHS)

TIPRANKS
·
May 15

Keros Therapeutics Q1 FY26 turns to net loss of USD 23.71 million; revenue drops to USD 367,000

Reuters
·
May 14

Keros Therapeutics announces annual shareholder meeting notice

Reuters
·
Apr 23